Lexitas Pharma Services closed screening on a Phase 3 Dry Eye Disease study last week.
Public source
Publisher name
Public post
Patient screening is one of the most common reasons why a clinical trial timeline may be delayed, and one of the most underestimated. If screening becomes a bottleneck,…
Company
Lexitas Pharma Services
More than a CRO: Your Partner for Unmatched Expertise and Precision in Ophthalmology Research
- Industry
- Research Services
- Location
- Durham, US
- Company size
- 51–200 employees
About Lexitas Pharma Services
Lexitas is a clinical research organization dedicated exclusively to ophthalmology since 2011. With unmatched expertise and precision in ophthalmic research, we deliver tailored approaches, rigorous quality standards, and unwavering commitment to operational success. Our dedicated team of ophthalmic experts guides each study with deep scientific and clinical experience, offering customized solutions to meet your needs at every stage of development. We have extensive experience in posterior and anterior segments, as well as rare diseases. Service Offerings: -Regulatory strategy -Study design and protocol development -Endpoint evaluation and selection -Site selection, management and training -Clinical project management and monitoring -Medical monitoring -Data management & Biostatistics -Reading center -Medical Affairs & commercialization strategies
See moreLatest activity
Latest activity from Lexitas Pharma Services
4 signals
Presence & Recognition
Lexitas Pharma Services will attend the Ophthalmology Futures European Forum in London on Thursday, September 10, and the 44th Annual Congress of The European Society of Cataract and Refractive Surgeons on September 11-15.
Presence & Recognition
Lexitas Pharma Services supports sponsors with a commitment to scientific rigor, operational excellence, and patient-focused research.
Presence & Recognition
Lexitas Pharma Services Chief Medical Officer David J. Tanzer, MD will be in Los Angeles, CA for The Retina Society's 59th Annual Scientific Meeting from September 23-26.
Discover more
Similar signals
Similar public activity from other companies.
Customers & Market
Navitas Life Sciences
Navitas Life Sciences completed another non-smoker study with 14 days of subject housing for regulatory submission.
Customers & Market
InoRx
InoRx delivered site activation and Ethics Committee approval for a Phase I healthy-volunteer study of a rheumatoid arthritis molecule after a previous CRO struggled with a new Central Drugs Standard Control Organization (CDSCO) requirement for government site sourcing.
Customers & Market
Richmond Pharmacology
Richmond Pharmacology expanded its Pharmacovigilance services to provide flexible, inspection-ready support that can evolve alongside clinical development programmes.
Customers & Market
MAC Clinical Research
MAC Clinical Research has a fully-owned network of early and late phase clinics across the UK, enabling it to support Phase I-IV studies and drug development expertise.
Customers & Market
WEP Clinical